Newsroom

Keeping up with GAIA-BT

Everything from our partnerships, products and press.

Partnership7 OCT 2026

GAIA-BT Secures Exclusive Rights to HAETAE and HiRecon Under Definitive Technology Transfer Agreement with KRIBB

Awards & Grants22 SEP 2026

GAIA-BT Selected as a Resident Company at Seoul AI Hub

Client24 JUN 2026

GAIA-BT to Lead "AI Optimization" of Cyron Therapeutics' Cancer Drug Candidates

28 UPDATES

Company news

Partnership7 OCT 2026GAIA-BT Secures Exclusive Rights to HAETAE and HiRecon Under Definitive Technology Transfer Agreement with KRIBB
Awards & Grants22 SEP 2026GAIA-BT Selected as a Resident Company at Seoul AI Hub
Client24 JUN 2026GAIA-BT to Lead "AI Optimization" of Cyron Therapeutics' Cancer Drug Candidates
Partnership20 MAY 2026GAIA-BT Signs Letter of Intent with Prosilico for AI-Based Drug Discovery Collaboration
Partnership20 MAY 2026GAIA-BT Signs MOU with Korea Institute of Toxicology for Joint R&D

Media

GAIA-BT in the press

Published in
Interview12 OCT 2026
“GAIA-BT는 ‘AI 신약개발 회사’가 아닌 AI와 사람, 병원과 연구기관, 그리고 실제 환자에서 얻은 정보를 하나로 연결해 신약개발의 의사결정 방식을 바꾸는 운영시스템을 개발하는 회사입니다.”
— Dr. Yun Kyoung Kang, CEO of GAIA-BT
Read interview (opens Wowtale in a new tab)
InterviewWowtale“GAIA-BT는 ‘AI 신약개발 회사’가 아닌 AI와 사람, 병원과 연구기관, 그리고 실제 환자에서 얻은 정보를 하나로 연결해 신약개발의 의사결정 방식을 바꾸는 운영시스템을 개발하는 회사입니다.”[판교허브 밸류업] “바이오 AI 에이전트로 임상 실패 방어”…가이아비티의 담대한 도전12 OCT 2026 · Read (opens Wowtale in a new tab)